New 'Zipper' therapy aims to halt devastating nerve attacks
NCT ID NCT07420296
Summary
This study is testing whether adding a targeted drug (eculizumab) to standard treatment helps people recover better from sudden, severe attacks of neuromyelitis optica, a rare autoimmune disease that damages the optic nerves and spinal cord. About 198 adults who recently had an attack will be randomly assigned to receive either the new combination therapy or standard care alone. Researchers will measure improvements in vision and physical function over 24 weeks to see if the new approach works better and is safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDERS (NMOSD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University General Hospital, Department of Neurology
RECRUITINGTianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.